Download PDF
Am J Perinatol 2009; 26(9): 659-665
DOI: 10.1055/s-0029-1220793
© Thieme Medical Publishers

The Role of Complement in Neurodevelopmental Impairment following Neonatal Hypoxic-Ischemic Encephalopathy

Hany Aly1 , Mohamed T. Khashaba2 , Ayman Nada3 , Bothina M. Hasanen2 , Robert McCarter1 , Seth J. Schultz4 , Laura Gordon3 , Pamela W. Feldhoff4 , Herbert A. Lassiter4
  • 1Department of Pediatrics, the George Washington University and the Children's National Medical Center, Washington, DC
  • 2Department of Pediatrics, Mansoura University Children's Hospital, Mansoura, Egypt
  • 3Institute of Post Graduate Childhood Studies, Ain Shams University, Cairo, Egypt
  • 4Division of Neonatal Medicine and the Kasair Children's Hospital Research Institute, Department of Pediatrics, University of Louisville School of Medicine, Louisville, Kentucky
Further Information

Publication History

Publication Date:
23 April 2009 (online)

Also available at
    Permissions and Reprints

ABSTRACT

Evidence has accumulated implicating complement activation in the pathogenesis of acute post-hypoxic-ischemic cerebral injury in infants who develop hypoxic-ischemic encephalopathy (HIE). However, the relationship between complement activation and subsequent neurological impairment is not known. We tested the hypothesis that in human neonates, post-hypoxic-ischemic complement activation within the central nervous system is positively associated with the acquisition of subsequent neurodevelopmental abnormalities. This prospective study included 18 full-term infants diagnosed with HIE following resuscitation at birth and seven control infants. Cerebrospinal fluid (CSF) samples were obtained from all infants in the first 24 hours of life as part of routine investigations to exclude sepsis and meningitis. Concentrations of terminal complement complexes (TCC), complement component 9 (C9), and albumin were quantified by enzyme-linked immunosorbent assay in all CSF samples. Neurological examination and Denver Developmental Screening Test II were performed at 6 and 12 months of life. Of the 18 HIE subjects, nine died, six survived with significant neurological impairment, and three had normal neurological outcomes. In the CSF of the 15 HIE infants who died or survived with abnormal outcomes, the mean concentration of TCC was increased compared with controls (p = 0.026) and the mean C9 concentration appeared to be decreased but the difference was not statistically significant (p = 0.056). Similar to the TCC concentration, the concentration of albumin in the CSF was significantly increased in infants with abnormal outcomes (p = 0.005). This study indicates that complement activation following resuscitation at birth, as manifested by increased TCC in the CNS, is positively correlated with the combination of the development of subsequent neurological sequelae and death. Further study incorporating larger sample sizes will be required to confirm this association. This step is essential before clinical trials of complement inhibitors can be justified in human neonates who suffer birth asphyxia.

KEYWORDS

Terminal complement complex - complement 9 - asphyxia neonatorum - neurodisability

REFERENCES

  • 1 Carli G, Reiger I, Evans N. One-year neurodevelopmental outcome after moderate newborn hypoxic ischaemic encephalopathy.  J Paediatr Child Health. 2004;  40 217-220
    PubMedGoogle Scholar
  • 2 Itoo B A, Al-Hawsawi Z M, Khan A H. Hypoxic ischemic encephalopathy. Incidence and risk factors in North Western Saudi Arabia.  Saudi Med J. 2003;  24 147-153
    PubMedGoogle Scholar
  • 3 Horn M, Schlote W. Delayed neuronal death and delayed neuronal recovery in the human brain following global ischemia.  Acta Neuropathol. 1992;  85 79-87
    CrossrefPubMedGoogle Scholar
  • 4 Petito C K, Feldmann E, Pulsinelli W A, Plum F. Delayed hippocampal damage in humans following cardiorespiratory arrest.  Neurology. 1987;  37 1281-1286
    PubMedGoogle Scholar
  • 5 Petito C K, Pulsinelli W A. Delayed neuronal recovery and neuronal death in rat hippocampus following severe cerebral ischemia: possible relationship to abnormalities in neuronal processes.  J Cereb Blood Flow Metab. 1984;  4 194-205
    PubMedGoogle Scholar
  • 6 Scolding N J, Morgan B P, Houston A et al.. Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies.  J Neurol Sci. 1989;  89 289-300
    CrossrefPubMedGoogle Scholar
  • 7 Singhrao S K, Neal J W, Rushmere N K, Morgan B P, Gasque P. Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis.  Am J Pathol. 2000;  157 905-918
    CrossrefPubMedGoogle Scholar
  • 8 Cowell R M, Plane J M, Silverstein F S. Complement activation contributes to hypoxic-ischemic brain injury in neonatal rats.  J Neurosci. 2003;  23 9459-9468
    PubMedGoogle Scholar
  • 9 Imm M D, Feldhoff P W, Feldhoff R C, Lassiter H A. The administration of complement component C9 augments post-ischemic cerebral infarction volume in neonatal rats.  Neurosci Lett. 2002;  325 175-178
    CrossrefPubMedGoogle Scholar
  • 10 Lassiter H A. The role of complement in neonatal hypoxic-ischemic cerebral injury.  Clin Perinatol. 2004;  31 117-127
    PubMedGoogle Scholar
  • 11 Lindsberg P J, Ohman J, Lehto T et al.. Complement activation in the central nervous system following blood-brain barrier damage in man.  Ann Neurol. 1996;  40 587-596
    CrossrefPubMedGoogle Scholar
  • 12 Schultz S J, Aly H, Hasanen B M et al.. Complement component 9 activation, consumption, and neuronal deposition in the post-hypoxic-ischemic central nervous system of human newborn infants.  Neurosci Lett. 2005;  378 1-6
    CrossrefPubMedGoogle Scholar
  • 13 Gilstrap LC, Oh W Guidelines for Perinatal Care. In. 5th ed. Elk Grove Village, IL; American Academy of Pediatrics & American Colloge of Obstetrics and Gynecology 2002
    Google Scholar
  • 14 Sarnat H B, Sarnat M S. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study.  Arch Neurol. 1976;  33 696-705
    CrossrefPubMedGoogle Scholar
  • 15 Frankenburg W K, Dodds J B. The Denver developmental screening test.  J Pediatr. 1967;  71 181-191
    PubMedGoogle Scholar
  • 16 Matsell D G, Roy III S, Tamerius J D et al.. Plasma terminal complement complexes in acute poststreptococcal glomerulonephritis.  Am J Kidney Dis. 1991;  17 311-316
    PubMedGoogle Scholar
  • 17 del Zoppo G, Ginis I, Hallenbeck J M et al.. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia.  Brain Pathol. 2000;  10 95-112
    PubMedGoogle Scholar
  • 18 Volanakis J EFM. The human complement system in health and disease. In: Dekker M New York; Marcel Dekker 1998
  • 19 del Zoppo G J. Microvascular responses to cerebral ischemia/inflammation.  Ann N Y Acad Sci. 1997;  823 132-147
    CrossrefPubMedGoogle Scholar
  • 20 Volpe J. Neurology of the Newborn. 4th ed. Philadelphia; W.B. Saunders 2001
    Google Scholar
  • 21 Plumb M ESJ. Proteins of the membrane attack complex. In: Volanakis JE, Frank MM The Human Complement System in Health and Disease. New York; Marcel Dekker 1998: 119-148
    Google Scholar
  • 22 Lipton P. Ischemic cell death in brain neurons.  Physiol Rev. 1999;  79 1431-1568
    PubMedGoogle Scholar
  • 23 Weisman H F, Bartow T, Leppo M K et al.. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.  Science. 1990;  249 146-151
    CrossrefPubMedGoogle Scholar
  • 24 Vakeva A P, Agah A, Rollins S A et al.. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy.  Circulation. 1998;  97 2259-2267
    PubMedGoogle Scholar
  • 25 Lindsay T F, Hill J, Ortiz F et al.. Blockade of complement activation prevents local and pulmonary albumin leak after lower torso ischemia-reperfusion.  Ann Surg. 1992;  216 677-683
    PubMedGoogle Scholar
  • 26 Hill J, Lindsay T F, Ortiz F et al.. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat.  J Immunol. 1992;  149 1723-1728
    PubMedGoogle Scholar
  • 27 Eppinger M J, Deeb G M, Bolling S F, Ward P A. Mediators of ischemia-reperfusion injury of rat lung.  Am J Pathol. 1997;  150 1773-1784
    PubMedGoogle Scholar
  • 28 Brock R W, Nie R G, Harris K A, Potter R F. Kupffer cell-initiated remote hepatic injury following bilateral hindlimb ischemia is complement dependent.  Am J Physiol Gastrointest Liver Physiol. 2001;  280 G279-G284
    PubMedGoogle Scholar
  • 29 Spain D A, Fruchterman T M, Matheson P J et al.. Complement activation mediates intestinal injury after resuscitation from hemorrhagic shock.  J Trauma. 1999;  46 224-233
    CrossrefPubMedGoogle Scholar
  • 30 Pemberton M, Anderson G, Vetvicka V, Justus D E, Ross G D. Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle.  J Immunol. 1993;  150 5104-5113
    PubMedGoogle Scholar
  • 31 Hill J H, Ward P A. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats.  J Exp Med. 1971;  133 885-900
    CrossrefPubMedGoogle Scholar
  • 32 Huang J, Kim L J, Mealey R et al.. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein.  Science. 1999;  285 595-599
    CrossrefPubMedGoogle Scholar
  • 33 Van Beek J, Chan P, Bernaudin M et al.. Glial responses, clusterin, and complement in permanent focal cerebral ischemia in the mouse.  Glia. 2000;  31 39-50
    CrossrefPubMedGoogle Scholar
  • 34 Vasthare U S, Barone F C, Sarau H M et al.. Complement depletion improves neurological function in cerebral ischemia.  Brain Res Bull. 1998;  45 413-419
    CrossrefPubMedGoogle Scholar
  • 35 Xiong Z Q, Qian W, Suzuki K, McNamara J O. Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration.  J Neurosci. 2003;  23 955-960
    PubMedGoogle Scholar
  • 36 Ten V S, Sosunov S A, Mazer S P et al.. C1q-deficiency is neuroprotective against hypoxic-ischemic brain injury in neonatal mice.  Stroke. 2005;  36 2244-2250
    CrossrefPubMedGoogle Scholar
  • 37 Figueroa E, Gordon L E, Feldhoff P W, Lassiter H A. The administration of cobra venom factor reduces post-ischemic cerebral injury in adult and neonatal rats.  Neurosci Lett. 2005;  380 48-53
    CrossrefPubMedGoogle Scholar
  • 38 Reviewers CIGA . Human albumin administration in critically ill patients: systematic review of randomized controlled trials. Cochrane Injuries Group Albumin Reviewers.  BMJ. 1998;  317 235-240
    PubMedGoogle Scholar
  • 39 Kattwinkel J Neonatal Resuscitation Textbook. 5th ed. Elk Grove Village, IL; American Academy of Pediatrics and American Heart Association 2006
    Google Scholar
  • 40 Stevens R W, Elmendorf D, Gourly M, Stroebel E, Gaafar H. Application of fluoroimmunoassay to cerebrospinal fluid immunoglobulin G and albumin.  J Clin Microbiol. 1979;  10 346-350
    PubMedGoogle Scholar
  • 41 Hallioglu O, Topaloglu A K, Zenciroglu A, Duzovali O, Yilgor E, Saribas S. Denver developmental screening test II for early identification of the infants who will develop major neurological deficit as a sequelae of hypoxic-ischemic encephalopathy.  Pediatr Int. 2001;  43 400-404
    CrossrefPubMedGoogle Scholar

Hany AlyM.D. 

900 23rd Street, NW

Suite G-2092, Washington, DC 20037

Email: haly@mfa.gwu.edu